Logo image of LAB

STANDARD BIOTOOLS INC (LAB) Stock Fundamental Analysis

NASDAQ:LAB - Nasdaq - US34385P1084 - Common Stock - Currency: USD

1.16  -0.07 (-5.69%)

After market: 1.15 -0.01 (-0.86%)

Fundamental Rating

3

Taking everything into account, LAB scores 3 out of 10 in our fundamental rating. LAB was compared to 55 industry peers in the Life Sciences Tools & Services industry. LAB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LAB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LAB has reported negative net income.
LAB had a negative operating cash flow in the past year.
In the past 5 years LAB always reported negative net income.
LAB had a negative operating cash flow in each of the past 5 years.
LAB Yearly Net Income VS EBIT VS OCF VS FCFLAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of LAB (-30.20%) is worse than 78.18% of its industry peers.
With a Return On Equity value of -39.20%, LAB is not doing good in the industry: 63.64% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -30.2%
ROE -39.2%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LAB Yearly ROA, ROE, ROICLAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

With a Gross Margin value of 48.31%, LAB perfoms like the industry average, outperforming 49.09% of the companies in the same industry.
LAB's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for LAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.13%
GM growth 5Y-2.51%
LAB Yearly Profit, Operating, Gross MarginsLAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

4

2. Health

2.1 Basic Checks

LAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
LAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LAB Yearly Shares OutstandingLAB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
LAB Yearly Total Debt VS Total AssetsLAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

LAB has an Altman-Z score of -0.56. This is a bad value and indicates that LAB is not financially healthy and even has some risk of bankruptcy.
LAB has a Altman-Z score of -0.56. This is in the lower half of the industry: LAB underperforms 78.18% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that LAB is not too dependend on debt financing.
The Debt to Equity ratio of LAB (0.00) is better than 74.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.56
ROIC/WACCN/A
WACC10.66%
LAB Yearly LT Debt VS Equity VS FCFLAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 5.70 indicates that LAB has no problem at all paying its short term obligations.
LAB's Current ratio of 5.70 is fine compared to the rest of the industry. LAB outperforms 78.18% of its industry peers.
A Quick Ratio of 5.09 indicates that LAB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.09, LAB is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.7
Quick Ratio 5.09
LAB Yearly Current Assets VS Current LiabilitesLAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

LAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.29%, which is quite impressive.
Looking at the last year, LAB shows a very strong growth in Revenue. The Revenue has grown by 64.02%.
The Revenue has been growing by 8.28% on average over the past years. This is quite good.
EPS 1Y (TTM)35.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64%
Revenue 1Y (TTM)64.02%
Revenue growth 3Y10.13%
Revenue growth 5Y8.28%
Sales Q2Q%65.74%

3.2 Future

The Earnings Per Share is expected to grow by 24.43% on average over the next years. This is a very strong growth
LAB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.22% yearly.
EPS Next Y52.25%
EPS Next 2Y30.27%
EPS Next 3Y24.43%
EPS Next 5YN/A
Revenue Next Year-1.17%
Revenue Next 2Y5.57%
Revenue Next 3Y6.69%
Revenue Next 5Y8.22%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
LAB Yearly Revenue VS EstimatesLAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M
LAB Yearly EPS VS EstimatesLAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LAB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LAB Price Earnings VS Forward Price EarningsLAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LAB Per share dataLAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as LAB's earnings are expected to grow with 24.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.27%
EPS Next 3Y24.43%

More info and screens

0

5. Dividend

5.1 Amount

LAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STANDARD BIOTOOLS INC

NASDAQ:LAB (4/25/2025, 7:06:54 PM)

After market: 1.15 -0.01 (-0.86%)

1.16

-0.07 (-5.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-26 2025-02-26/amc
Earnings (Next)05-07 2025-05-07
Inst Owners73.38%
Inst Owner ChangeN/A
Ins Owners1.75%
Ins Owner Change22.25%
Market Cap439.63M
Analysts80
Price Target2.42 (108.62%)
Short Float %4.25%
Short Ratio9.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.15%
Min EPS beat(2)-27.3%
Max EPS beat(2)22.99%
EPS beat(4)1
Avg EPS beat(4)-44.99%
Min EPS beat(4)-135.88%
Max EPS beat(4)22.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)8.04%
Min Revenue beat(2)7.49%
Max Revenue beat(2)8.6%
Revenue beat(4)2
Avg Revenue beat(4)-2.39%
Min Revenue beat(4)-23.66%
Max Revenue beat(4)8.6%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-22.97%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.14%
EPS NY rev (1m)-18.18%
EPS NY rev (3m)-18.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.06%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.52
P/FCF N/A
P/OCF N/A
P/B 0.93
P/tB 1.33
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS0.46
BVpS1.24
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.2%
ROE -39.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.31%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.13%
GM growth 5Y-2.51%
F-Score5
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 49.55%
Cap/Sales 4.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.7
Quick Ratio 5.09
Altman-Z -0.56
F-Score5
WACC10.66%
ROIC/WACCN/A
Cap/Depr(3y)31.23%
Cap/Depr(5y)51.75%
Cap/Sales(3y)3.79%
Cap/Sales(5y)6.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64%
EPS Next Y52.25%
EPS Next 2Y30.27%
EPS Next 3Y24.43%
EPS Next 5YN/A
Revenue 1Y (TTM)64.02%
Revenue growth 3Y10.13%
Revenue growth 5Y8.28%
Sales Q2Q%65.74%
Revenue Next Year-1.17%
Revenue Next 2Y5.57%
Revenue Next 3Y6.69%
Revenue Next 5Y8.22%
EBIT growth 1Y-113.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.74%
EBIT Next 3Y33.81%
EBIT Next 5Y23.48%
FCF growth 1Y-229.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-231.4%
OCF growth 3YN/A
OCF growth 5YN/A